Erratum: Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters


Published Version doi:10.1038/s41523-017-0031-9

Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34491865

Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Erratum: Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo

Jason J. Zoeller¹, Roderick T. Bronson², Laura M. Selfors¹, Gordon B. Mills³ and Joan S. Brugge¹

npj Breast Cancer (2017); 3:38; doi:10.1038/s41523-017-0031-9

Erratum to: npj Breast Cancer (2017); doi:10.1038/s41523-017-0020-z; Published 01 May 2017

Two references were mistakenly omitted from the first sentence of the introduction.

Original text:
Extracellular matrix (ECM) proteins produced by diverse tumor types protect tumor cells from death in response to various agents.1,2,3,4


Corrected text:
Extracellular matrix (ECM) proteins produced by diverse tumor types protect tumor cells from death in response to various agents.1,2,3,4,5,6


All subsequent references have been renumbered accordingly. These errors have now been corrected in the HTML and PDF versions of this article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017

¹Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA; ²Rodent Histopathology Core, Harvard Medical School, Boston, MA, USA and ³Systems Biology, UT MD Anderson Cancer Center, Houston, TX, USA

Correspondence: Joan S. Brugge (joan_brugge@hms.harvard.edu)

Published online: 22 September 2017

Published in partnership with the Breast Cancer Research Foundation